Updated: Sep 19, 2021
A peer review has claimed that global use of ivermectin can end the COVID-19 pandemic, as it considerably reduces the risk of developing fatal respiratory disease on a regular basis. The common anti-parasitic ivermectin is being promoted by doctors and campaigners worldwide as a miracle cure for COVID-19. This study was evaluated by medical experts, including three senior US government scientists, and the most comprehensive review of data available from clinical, in vitro, animal and real-world studies. It is published in the US Journal.
During a review of published peer review studies, manuscripts, meta-analysis experts and epidemiological tests in regions with ivermectin distribution efforts, led by the Front Line COVID-19 Critical Care Alliance (FLCCC), a group of medical and scientific experts showed that ivermectin is an effective prophylaxis- and treatment of COVID-19.
They did the work that the medical authorities failed to do, according to the researchers. The most comprehensive examination has been done on the available data on ivermectin and the gold standard has been used to qualify the reviewed data before ivermectin can end the pandemic. The manuscript focused on 27 controlled tests, 15 of which were randomised controlled trials (RCT’s), available in January 2021. Most regions worldwide now recognise the strong prophylaxis and treatment of Covid-19 with ivermectin.
Ivermectin approved for use in India as well
The drug has been approved for use by medical professionals by South Africa, Zimbabwe, Slovakia, the Czech Republic, Mexico and India. The results of this last study show that the distribution campaigns for ivermectin repeatedly led to “rapid decreases in morbidity and mortality across the entire population.” Researchers called on regional public health authorities and physicians worldwide to demand that ivermectin be incorporated immediately in their standard of care so that we can end this pandemic once and for all.
ccording to the researchers, patients with persistent Covid-19 symptoms who completed a six-week supervised rehabilitation programme demonstrated significant improvements in exercise capacity, respiratory symptoms, fatigue, and cognition, including one of Indian ancestry. The study discovered a statistically significant increase in exercise capacity, as measured by distance travelled and the ability to continue walking without stopping, using incremental and endurance shuttle-walking tests.
Additionally, as measured by standardised clinical assessment tools, participants demonstrated improvements in their overall wellbeing and cognition. The small but significant study, published in the journal Chronic Respiratory Disease, followed thirty patients who participated in twice-weekly face-to-face exercise rehabilitation classes.